Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| Derived | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | SEK | Delayed | ||
| BATS Europe | GBP | Delayed | ||
| OTC Markets | USD | Delayed | ||
| NASDAQ | USD | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
AstraZeneca (AZN) announced positive interim results from a Phase III trial for Imfinzi (durvalumab) plus standard-of-care chemotherapy as a first-line treatment for patients...
AstraZeneca (AZN) and Daiichi Sankyo announces a clinical trial collaboration and supply agreement with a subsidiary of Merck (MRK).The agreement looks to evaluate the...
By Samuel IndykInvesting.com – At 07:36BST, FTSE 100 Futures are trading higher by 0.2% at 7212.In FX markets, GBP/USD is trading at 1.3768, EUR/GBP is trading at 0.8462. The US...
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5...
The stocks of the vaccine producers have gained a lot during 2021 due to the wide vaccination campaign around the world. Still, the COVID-19 pandemic is still not over as the virus...
Europeans Vaccinated With AstraZeneca Should Be Able To Enter US, Says EUAuthored by Lorenz Duschamps via The Epoch Times,People who have received two doses of...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Neutral | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Strong Sell | Sell | Strong Buy | Strong Buy |
| Summary | Strong Sell | Strong Sell | Neutral | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 1,430.00 | 1,440.00 | 1,381.50 | +37.00 | +2.66% | 726.99K | London | |||
| 1,481.00 | 1,484.50 | 1,445.00 | +43.50 | +3.03% | 853.13K | London | |||
| 4,858.00 | 4,889.00 | 4,839.00 | +8.0 | +0.17% | 457.94K | London | |||
| 1,128.00 | 1,130.00 | 1,086.00 | +36.00 | +3.30% | 177.08K | London | |||
| 145.00 | 145.00 | 145.00 | 0.00 | 0.00% | 166.00 | London | |||
| 31.50 | 31.50 | 31.50 | -3.00 | -8.70% | 41.60K | London | |||
| 4.20 | 4.21 | 4.08 | -0.34 | -7.66% | 12.13M | London | |||
| 3.50 | 3.50 | 3.50 | 0.00 | 0.00% | 29.17K | London | |||
| 3.80 | 3.90 | 3.80 | -0.5500 | -13.10% | 11.33M | London | |||
| 1.55 | 1.55 | 1.55 | 0.000 | 0.00% | 101.13K | London | |||
| 3.95 | 3.95 | 3.95 | 0.00 | 0.00% | 200.00K | London | |||
| 12.25 | 12.25 | 12.25 | -1.50 | -10.91% | 2.07M | London | |||
| 0.18 | 0.00 | 0.00 | -0.015 | -7.69% | 15.71M | London | |||
| 1.39 | 1.39 | 1.39 | +0.005 | +0.36% | 673.26K | London | |||
| 1.225 | 1.225 | 1.225 | -0.125 | -9.26% | 4.77M | London |
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.